Amgen (AMGN) Tops Q4 EPS by 14c; Guides FY19 Below the Street
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amgen Reports Fourth Quarter And Full Year 2018 Financial Results
January 29, 2019 4:01 PM ESTTHOUSAND OAKS, Calif., Jan. 29, 2019 /PRNewswire/ --Â Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year 2018 in comparison to comparable periods in 2017. Key results include:
For the fourth quarter, total revenues increased 7 percent to $6.2 billion. Product sales grew 8 percent globally. New and recently launched products including Repatha® (evolocumab), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab) showed double-digit growth.For the full year, total revenues increased 4 percent to $23.7 billion, with 3 percent product sales growth.... More